Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.
A limb-girdle muscular dystrophy gene therapy Sarepta licensed last year faces its first clinical test.
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.